Results 11 to 20 of about 93,945 (299)

Outcome of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in non-metastatic locally advanced non-small cell lung cancer – A prospective and randomized study [PDF]

Asian Journal of Medical Sciences, 2023
Background: Sequential chemoradiotherapy and concurrent chemoradiotherapy are two treatment options for locally advanced non-small cell lung cancer (NSCLC). Still there is limited data regarding which is the better treatment option.
Subir Pal , Anjan Bera , Soumen Mukherjee , Asmita Dasgupta , Srikrishna Mandal , Saptarshi Banerjee   +5 more
doaj   +2 more sources

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]

, 2006
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael, Aubert, Delphine, Flentje, Michael, Semrau, Sabine, Fietkau, Rainer, Fittipaldo, Alberto, Huber, Rudolf M., Kleine, Philip, Beckmann, Gabriele   +8 more
core   +1 more source

Impact of Radiotherapy, Chemotherapy and Surgery in Multimodal Treatment of Locally Advanced Esophageal Cancer [PDF]

, 2011
Objectives: It was the aim of this study to assess our institutional experience with definitive chemoradiation (CRT) versus induction chemotherapy followed by CRT with or without surgery (C-CRT/S) in esophageal cancer.
Annina Lemminger, Stahlberg, Katharina, Lemminger, Annina, Claus Belka, Bleif, Martin, Bamberg, Michael, Katharina Stahlberg, Martin Bleif, Belka, Claus, Berger, Bernhard, Bernhard Berger, Michael Bamberg   +11 more
core   +1 more source

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer [PDF]

, 2012
BACKGROUND: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population.
Bilgen, E.J.S., van Lanschot, J. J. B., Piet, A. H. M., Dekken, H. (Herman) van, Lanschot, J.J.B. van, Punt, C.J.A., Ten Kate, F.J.W., Spaander, Manon, Hospers, G.A.P. (Geke), Beukema, JC, Steyerberg, E.W., van Lanschot, Jan, Reinders, J.G., Hospers, G. A. P., van der Sangen, M.J.C., Hagen, P. (Pieter) van, van der Gaast, A., Wijnhoven, B.P.L., Kate, F.J.W. Ten, Wijnhoven, B.P.L. (Bas), Tilanus, H. W., Berge Henegouwen, M.I. (Mark) van, van Dekken, H (Herman), Rij, C. van, Nieuwenhuijzen, G.A.P., Piet, A.H.M., Cuesta, M.A. (Miguel), Creemers, G.-J., Henegouwen, MIV, Richel, D.J., Hulshof, M. C. C. M., Busch, O.R.C., Gaast, A. van der, Biermann, Katharina, Dekken, H. van, Verheul, HMW, Spillenaar Bilgen, E. J., ten Kate, F. J. W., van Rij, Caroline, Tilanus, H.W. (Hugo), Hulshof, MCCM, Wijnhoven, B. P. L., Plukker, J. T. M., Punt, CJA, Spillenaar Bilgen, E.J. (Ernst Jan), Biermann, K., Bonenkamp, J.J. (Han), Nieuwenhuijzen, G. A. P., Steyerberg, E. W., Bonenkamp, J.J., Rozema, T., Henegouwen, M. I. van Berge, Tilanus, H.W., van der Gaast, Ate, van Hagen, P., Sangen, M.J.C. van der, Bilgen, EJS, Busch, ORC, Punt, C.J.A. (Cornelis), van Dekken, H., Lanschot, J.J.B. (Jan) van, Busch, O. R. C., Plukker, JTM, Richel, DJ, Piet, AHM, Reinders, J.G.P. (Jurrien), Reinders, JG, Kate, Fiebo, van Rij, C., Busch, O.R.C. (Olivier), Cuesta, MA, Bilgen, E. J. Spillenaar, Nieuwenhuijzen, GAP, Beukema, J. C., Rozema, T. (Tom), Verheul, H.M.W. (Henk), Verheul, H. M. W., Creemers, G.J.M. (Geert-Jan), Gaast, A. (Ate) van der, Tilanus, Hugo, Hulshof, M.C.C.M. (Maarten), Bonenkamp, J. J., van Berge Henegouwen, M. I., Steyerberg, E.W. (Ewout), Punt, C. J. A., Richel, D. J., Beukema, J.C. (Jannet), Sangen, M.J.C. (Maurice) van der, Bonenkamp, JJ, Kate, F.J.W. (Fiebo) ten, Wijnhoven, Bas, Creemers, G.J., Verheul, H.M.W., Hagen, Pieter, Hospers, GAP, Blaisse, R. J. B., Rozema, T, Steyerberg, Ewout, Hagen, P. van, Rij, C.M. (Caroline) van, Cuesta, M. A., Hulshof, M.C.C.M., Plukker, J.T. (John), Cuesta, M.A., Blaisse, RJB, Henegouwen, M.I.V., Piet, A.H.M. (A. H M), Richel, D.J. (Dirk), van Rij, C. M., Beukema, J. C.; id_orcid, Blaisse, R.J.B., Hospers, G.A.P., Plukker, J.T.M., van Lanschot, J.J.B., van der Sangen, M. J. C., Creemers, GJ, Creemers, G. -J., Beukema, J.C., Reinders, J. G., Biermann, K. (Katharina), van der Sangen, MJC, Nieuwenhuijzen, G.A.P. (Gerard)   +121 more
core   +3 more sources

The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study [version 1; peer review: 2 approved]

NIHR Open Research, 2021
Background: Neoadjuvant cancer treatment is associated with improved survival following major oesophagogastric cancer surgery. The impact of neoadjuvant chemo/chemoradiotherapy on physical fitness and operative outcomes is however unclear.
Lisa Loughney, Gareth Ambler, Thomas Owen, Michael G. Mythen, Denny Z.H. Levett, Gerard Danjoux, Jamie J. Kelly, Peter M.A. Calverley, Michael P.W. Grocott, Sandy Jack, Zachos Anastasiou, Malcolm A. West   +11 more
doaj   +1 more source

Chemoradiotherapy

, 2023
On June 8 my brain was irradiated with megavoltage X-rays for the last time — ever. I had mixed feelings about this. On the one hand, I was glad to be done with this phase of treatment. Just over two months previously I'd been diagnosed with glioblastoma, a terminal, incurable, and highly aggressive form of brain cancer.
openaire   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma

Technology in Cancer Research & Treatment, 2021
Purpose: Induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma.
Guoqiang Xu MD, Qiaoli Wang MD, Xingrao Wu MD, Chunyan Lv MD, Guilin Zeng MD, Zhihong Xue MD, Ruixue Cao MD, Nan Zhang BD, Wei Xiong PhD, Qin Huang MD   +9 more
doaj   +1 more source

The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma

Medicina, 2021
Background and Objectives: There is evidence or consensus on the use of 18F-2-fluorodeoxyglucose-positron emission tomography with computed tomography (PET-CT) in evaluating the effects of treatment at 12 weeks after chemoradiotherapy for head and neck ...
Hoshino Terada, Yuzo Shimode, Madoka Furukawa, Yuichiro Sato, Nobuhiro Hanai   +4 more
doaj   +1 more source

Complete pathologic response as a prognostic factor for squamous cell carcinoma of the oropharynx post-chemoradiotherapy

, 2015
INTRODUCTION: Chemoradiotherapy for squamous cell carcinoma of the oropharynx (SCCO) provides good results for locoregional disease control, with high rates of complete clinical and pathologic responses, mainly in the neck.
Auro Del Giglio (12813424), Thaiana Aragão Santana (12798950), Damila Cristina Trufelli (10411802), Leandro Luongo de Matos (6122135), Fábio de Aquino Capelli (12813421), Gilberto de Castro Junior (12813427), Jossi Ledo Kanda (12813079)   +6 more
core   +1 more source